# Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

> **NCT03599453** · EARLY_PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 8 (actual)

## Conditions studied

- Triple -Negative Breast Cancer
- Estrogen Receptor Negative
- HER2/Neu Negative
- Anatomic Stage IV Breast Cancer AJCC
- Progesterone Receptor Negative

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Chemokine Modulation Therapy
- **DRUG:** Celecoxib
- **BIOLOGICAL:** Recombinant Interferon Alfa-2b
- **DRUG:** Rintatolimod
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03599453
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-09
- **Primary completion:** 2020-09-02
- **Final completion:** 2023-03-21
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03599453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03599453, "Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03599453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*